Thursday, March 17, 2011

Wild Desert Tepin Pepper

SIRTAP EV 1F 1G 1F 10ML

Active ceftriaxone therapy group OTHER DISODIUM
beta-lactam antibacterial
Product Type DRUG USE ONLY MAKES NO HOSPITAL NHS scheme
Class H Type Recipe OSP
Form Farm. INJECTIONS Container BOX
Commerc Data valid for 24 months. 06/03/2006
ATC J01DD04
Producer Price SO.SE.PHARM Srl



NAME
SIRTAP

Pharmacotherapeutic
Antibacterials for systemic use.

ACTIVE
500 mg / ml powder and 2 solvent for solution for injection for use intr
amuscolare: ceftriaxone disodium 3.5 H 2 O 596.5 mg equivalent to ceftriaxone 500 mg
. 1 g / 3.5 ml powder and solvent for solution for injection: there
ftriaxone disodium 3.5 H 2 O equal to 1.193 g ceftriaxone 1 g. 1 g / 10
ml powder and solvent for solution for injection for intravenous use: there
ftriaxone disodium 3.5 H 2 O equal to 1.193 g ceftriaxone 1 g. 2 g powder for solution for infusion
re: ceftriaxone disodium 3.5 H 2 O 2.386 g
equal to 2 g ceftriaxone

EXCIPIENTS
powder and solvent for solution for intramuscular injection: the
a solvent ampoules containing lidocaine hydrochloride. Powder and solvent for
solution for injection for intravenous use: the solvent ampoule contains
water for injections. INDICATIONS


use in specific elective and severe bacterial infections of confirmed or suspected source
Gram-negative "difficult" or mixed flora with
presence of Gram-negative resistance to the most 'common antibiotics. In pa rticle
the product is indicated in these infections,
debilitated patients and / or immunocompromised. Prophylaxis of infections chiru
rgiche.

CONTRAINDICATIONS / EFF.SECONDAR
hypersensitivity 'to cephalosporins or any of the excipients
i. In case of hypersensitivity 'to penicillins, it should be borne in mind
and the possible occurrence of cross-allergy. In women in the state of
pregnancy and early childhood
the product should be administered in cases of real need 'and under the direct control of the average
co. Hyperbilirubinemic premature infants and should not be treated with ceftriaxone
ati. In vitro studies have shown that ceftriaxone
p u 'move bilirubin from its plasma albumin binding sites
tical and it' possible that these patients will develop bilirubin encephalopathy
ia. Treatment with calcium, because of the risk of
tion form of precipitation of ceftriaxone-calcium salts in infants born at term
na.

DOSAGE
Scheme General dosage. Adults and children over 12 years: The dose and co
nsigliata 'of 1 g of the drug once a day (every 24 hours). In most cases
'severe or moderate infections caused by microorganisms sensitive
, the dose can' reach 4 g administered in a single
s olution. Infants (up to 2 weeks) and the daily dose 'of 20-5
0 mg / kg body weight once, because of immatu
rita' of their enzyme systems should not exceed 50 mg / kg
. Children (from 3 weeks to 12 years): The daily dose can '
vary between 20 and 80 mg / kg. For intravenous doses equal to or greater than 50 mg / kg is recommended to use a perfusion
lasting less than 30 minutes
you. For children weighing over 50 kg andra 'p
roprio the dosage used in adults. Elderly: The dosage regimen of adults re
calls for changes in elderly patients. The duration of Apia and
b 'depending on the course of the infection. Like all
treatment with antibiotics, in general the drug is
lasted for a minimum of 48-72 hours after sfebbramento or after
stration of complete eradication of bacteria. Prophylaxis of surgical infections
ions: for the prevention of post-operative infections v
erranno given in relation to risk of contamination
and type of intervention, 1 g im or 1-2 g IV single dose, one hour before
intervention. Dosing in Renal ren
ale particular conditions: in patients with creatinine clearance greater than 10 ml / min
the dose remains unchanged. In the case of creatinine clearance u
Guale or less than 10 ml / min can be 'given up to a maximum of
2 g once a day. Hepatic impairment: normal dosage. The
nsufficienza renal and hepatic association: controlling the plasma concentrations must
ceftriaxone. Premature maximum dose 50 mg / kg vo lta
day. Method of administration from the point of view Microbiol
OGIC the product should be used immediately after reconstitution
institution. If not used immediately, conditions and
the period of storage prior to use are the responsibility 'of the user
. The stability 'of the medicinal chemistry and physics after reconstitution and'
been demonstrated for 24 hours at +2 degrees C to +8 degrees C for 6 hours p er
the product stored at temperatures below 25 degrees C. Possoni
or vary in color from pale yellow to amber depending on concentration and
of the retention period;
this characteristic has no influence on the efficacy or tolerability 'of the drug. So
solution for intramuscular injection intramuscular
to practice, and dissolve the drug with the appropriate im solvent (solution of them
docaina 1%) and that 'Sirtap 2 ml per 500 mg, and 3.5 ml per g
Sirtap 1: inject the solution tank so deeply' n obtained
el buttock, alternating in the buttocks subsequent injections. The solution
and lidocaine should not be administered intravenously. Solution for u know
to practice intravenous IV injection, dissolve the drug co
n the appropriate solvent (water for injections) and that '
0 of 1 ml per ml Sirtap 1 g, and injected directly into a vein in time
for 2-4 minutes. Intravenous perfusion: to practice perfusion
dares to dissolve the drug intravenously at a rate of 2 g in 40 ml of liquid for melting
free calcium ions (saline solution Gluc
daring to 5% or 10%, 5% fructose solution, a solution glucosat
in dextran 6%). Perfusion will have 'a period of less than 30 minutes
you. The solutions of the drug should not be mixed in solutions containing other antimicrobial drugs
oni solutions or diluents
different from those listed above for possible incompatibility '.


STORAGE No special precautions for storage.

WARNINGS
The drug is eliminated by around 56% through the urine, and
the remaining 44% through the bile in the form
microbiologically active. Faeces and 'this predominantly in an inactive form. If
reduced functionality 'renal' share dropped in most 'high for v ia
bile in the faeces. Since 'even under these circumstances the time
half-life is only slightly increased in most c asi
not' need to reduce the dosage of the drug, provided that the functionality and
'liver is normal. Only in the presence of a gr
avissima renal insufficiency (creatinine clearance <= 10 ml/min
) the maintenance dose every 24 hours must 'be reduced to half'
than the usual dose. Like other cephalosporins, and '
was shown that ceftriaxone can' sit partially interfere with
the binding of bilirubin to albumin in plasma. It is recommended, q
uindi, caution in the treatment of newborns with the drug iperbilirubin
emic, especially if they are premature. The third generation cephalosporins, and other com
betalattamine can induce microbial resistance and the eve
provenance and 'more to opportunistic organisms, especially Enterobac
teriaceae and Pseudomonas, in immunocompromised individuals and probably at their most
ssociando between' betalattamine. As with any therapy
anti biotic, in case of prolonged treatment should be making regular checks of the lari
Peripheral blood counts. In extremely rare cases, in Pazi
bodies treated with high doses, the ultrasonography h in the gallbladder
revealed findings interpreted as thickening of the bil
e. This condition and 'promptly regressed interruption or term
ine therapy. Although these findings should be symptomatic
ici, only conservative treatment is recommended. Were
s signal in the course of treatment with cephalosporins, positivity 'of you
ST Coombs (sometimes false). Before starting treatment with the drug co
, a thorough investigation should be conducted to determine if the pa tient
expressed in the past hypersensitivity 'to cef
alosporine, penicillins and other drugs. The product must be added with caution
inistrato in patients allergic to penicillin since 's
ono described cases of hypersensitivity' cross between penicillins and Cephas
losporine. Because of immaturity 'of body functions, the premature re
should not be treated with higher doses of the product
50 mg / kg / day. As with other antibiotics, prolonged use can 'do
vorire the development of resistant bacteria and in case of superinfection
should take the most' appropriate. Possibility of acute hypersensitivity reactions
'may require the use of adrenaline and other measures of em
ergenza. Preparations containing lidocaine should not be administered intravenously
Istrate and patients allergic to this anesthetic
local. If you show signs of infection, the organism respon sible
should be isolated and appropriate therapy based on the sensitivity of you
st ', should be adopted. Coll
discusses several tests on samples before treatment should be performed to determine the sensitivity
'to ceftriaxone
the responsibility of the microorganism. Treatment with this medicine may 'still be initiated in appropriate
know the results of these tests, and treatment should still be
and, if necessary, amended according to the results of analysis
elle. Before using the drug in combination with others to
ntibiotici should be carefully re-read Instructions for '
use of other drugs to know any contraindications, av
litigation, precautions and adverse reactions. The 'renal
should be monitored carefully. Pseudomembranous colitis or are
been reported following the use of cephalosporins (and other broad-spectrum antibiotic
tical), and 'important to consider this diagnosis in patients who present pa
diarrhea after antibiotic use. The medicinal
and should not be mixed or administered simultaneously with sol
or products containing calcium ions, although infusions separately.
Solu tions or products containing calcium should not be given in the next 48 hours
last administration of the product. In neon
ati or preterm have been reported cases of fatal reaction to results
precipitation of calcium ceftriaxone in lungs and kidneys. In some cases, the s
omministrazione of the drug and that of calcium-containing solutions differed by
and infusion time.


INTERACTIONS This drug should not be added to solutions containing calcium, such as
Hartmann and Ringer solutions. The contemporary somministrazio
any of the product with high-dose diuretics for high activity '(eg
urosemide f) to high doses has not yet revealed disorders was
nzionalita' impairment. There is' no evidence that the product increases
the toxicity 'renal aminoglycoside. The ingestion of alcohol
following its success not by the drug 'effects similar to this
lli of disulfiram, ceftriaxone, in fact, does not contain the N-group
metiltiotetrazolico be held responsible for the intolerable
possible alliance of both alcohol hemorrhagic manifestations occurred
with other cephalosporins. The elimination of the drug is not '
amended by probenecid. It 'been shown in experimental conditions
synergistic action between the drug and aminoglycosides against many Gram-negative bacteria
. The strengthening of activity 'of these associations, although not always predictable
well, must' be held
into account all the serious infections resistant to other treatments, due to organisms such as Pseudomonas aeruginosa
. Due to incompatibility
'physical of the two drugs are administered separately at doses ra
ccomandate.

SIDE EFFECTS
Similar to what happens with other cephalosporins,
during therapy with the drug may occur in the following side effects: systemic
the medicine should not be mixed or somminis
trato simultaneously with calcium-containing solutions or products , anc
h, when infused separately. In newborns, premature and have been described
you cases of fatal reaction to ceftriaxone-calcium precipitates in lung and kidney
monitor. In some cases the drug and that the
of calcium-containing solutions differed by time and in
merger. Gastrointestinal Disorders: loose stools, diarrhea, nausea
, vomiting, stomatitis, glossitis, rarely thickening of the bile. Modi fications
Hematologic: eosinophilia, leukopenia, granulocytopenia,
ane mia, thrombocytopenia. Skin reactions: rash, allergic dermatitis,
itching, hives, and swelling. Other rare side effects: headache, dizziness
, increased transaminases, oliguria, increased values \u200b\u200bs
ierici creatinine, mycosis of the genital tract, chills, fever, and reactions
anaphylactic or anaphylactoid reactions. The onset of shock and anafilat
tico 'extremely rare and requires immediate measures like the S
omministrazione intravenous epinephrine followed by a glucocorticoid.
Rare cases of pseudomembranous enterocolitis and parameter changes and
mocoagulativi have been reported following the use of cephalosporins
. There have been reports of hemolytic anemia after treatment with
to cephalosporins. At the local level in rare cases have appeared Reaz
ions phlebitis after IV administration, and these reactions can be avoided by com
nque slow injection (2-4 minutes) of the drug.
intramuscular injection without lidocaine and 'painful. In subjects p
redisposti hypersensitivity reactions may occur '.

PREGNANCY AND LACTATION
in women who are pregnant, breast-feeding and the first
missima childhood, the product should be administered in cases of actual
it ceases' and under direct medical supervision.

0 comments:

Post a Comment